The latest price target for Arcus Biosciences (NYSE:RCUS) was reported by HC Wainwright & Co. on November 6, 2024. The analyst firm set a price target for $20.00 expecting RCUS to rise to within 12 months (a possible 38.12% upside). 23 analyst firms have reported ratings in the last year.

The latest analyst rating for Arcus Biosciences (NYSE:RCUS) was provided by HC Wainwright & Co., and Arcus Biosciences reiterated their neutral rating.

There is no last upgrade for Arcus Biosciences

There is no last downgrade for Arcus Biosciences.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arcus Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arcus Biosciences was filed on November 6, 2024 so you should expect the next rating to be made available sometime around November 6, 2025.

While ratings are subjective and will change, the latest Arcus Biosciences (RCUS) rating was a reiterated with a price target of $20.00 to $20.00. The current price Arcus Biosciences (RCUS) is trading at is $14.48, which is out of the analyst’s predicted range.